CA9 and renal cell carcinoma: On-target off-tumor toxicity of CAR T cells was first reported in a clinical trial of renal cell carcinoma (Phase 1) patients treated with CAR T cells recognizing carbonic anhydrase IX (CAIX) on bile duct epithelium along with the malignancy resulting in cholestasis [37].